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Human DNA repair mechanisms
The genome is continuously assaulted by reactive species with-
in cells (reactive oxygen species and various metabolites) and
by environmental agents from without (UV light, ionizing radia-
tion, and toxins). It is not surprising, therefore, that the human
genome encodes a large number of proteins, at least 130, that
function in DNA repair processes (Wood et al., 2001).
Several types of DNA repair processes are tailored to deal
with various types of damage, although some are overlapping
(reviewed in Hoeijmakers, 2001). For example, three types of
excision repair have been described: base excision repair
(BER), nucleotide excision repair (NER), and mismatch repair
(MMR). Small chemical alterations of bases (usually a result of
endogenous oxidation or alkylation) are generally repaired by
BER. Lesion-specific glycosylases cleave the damaged base(s)
from the sugar-phosphate backbone, and the damaged strand
is incised by an endonuclease at the abasic site. Local DNA
synthesis and ligation are employed to complete the repair,
either through the more commonly used short-patch BER path-
way or the more complex long-patch BER pathway. NER
removes bulky adducts such as pyrimidine dimers resulting
from exposure to various environmental agents. Multiprotein
complexes recognize and bind to the damage site, unwind the
duplex DNA, incise on either side of the damage, and remove
the damaged segment. DNA is then synthesized to fill the gap,
using the undamaged strand as a template, and the ends are
ligated. MMR corrects nucleotide mismatches that occur during
replication or recombination. Mismatches are recognized, multi-
ple factors are recruited to the site, the newly synthesized
strand is identified and degraded past the mismatch, and the
degraded stretch is resynthesized.
Two additional types of DNA repair, homologous recombi-
nation (HR) and nonhomologous end-joining (NHEJ), are
employed when the most serious type of DNA damage, a dou-
ble-strand break, occurs. HR is considered an error-free path-
way since it uses a copy (usually the sister chromatid available
during the S and G2 phases of the cell cycle) of the damaged
segment as a template to guide repair. NHEJ is considered an
error-prone pathway, since free ends are joined without the use
of a template or through use of very small microhomologous
repeats and, consequently, there often may be an associated
loss of nucleotides or translocation.
During the past few years, considerable progress has been
made in understanding how these repair processes might interact
and how specific disruptions of these mechanisms lead to
genomic instability and tumorigenesis. This review focuses on
three of the major findings in this regard: the identification of bial-
lelic germline mutations in MUTYH (previously called MYH) in
individuals with a predisposition to multiple colorectal adenomas
and carcinomas, the identification of the DNA repair protein
BRCA2 as a Fanconi anemia protein, and the recognition of a
potential key role of recQ-like helicases in the coordination of
DNA repair pathways due to their interaction with and recruitment
of numerous types of DNA repair proteins to sites of damage.
The BER gene MUTYH and colorectal cancer
Although oxidative DNA damage has been implicated in cancer
etiology, as of two years ago, there were no known human
genetic disorders attributed to BER defects. MUTYH, the
human homolog of the E. coli mutY gene encoding a DNA gly-
cosylase (Slupska et al., 1996), is the first BER gene associated
with a human cancer syndrome, as biallelic germline mutations
in MUTYH have been identified in individuals with a predisposi-
tion to multiple colorectal adenomas and carcinomas (Al-
Tassan et al., 2002).
Isolated adenomatous polyps are a common finding in the
colon, especially with advancing age; adenomatous polyps then
undergo malignant transformation to become carcinomas over
time. When multiple polyps are present, the likelihood of devel-
oping a carcinoma is directly related to their number, although
there are additional modifying factors (Debinski et al., 1996).
Germline truncating mutation of the APC tumor suppressor
gene is associated with an autosomal dominant colon cancer
predisposition syndrome known as familial adenomatous poly-
posis coli, or FAP. FAP is characterized by the presence of a
hundred to thousands of colorectal adenomas, early onset of
colorectal carcinoma, and variable extracolonic manifestations
(congenital hypertrophy of the retinal pigment epithelium, upper
GI tract polyposis, or desmoid tumors).Tumors develop after the
wild-type APC gene undergoes somatic mutation. The key role
of APC mutation in early tumor development is also indicated by
the fact that somatic mutations of APC are found in the great
majority of sporadic colorectal tumors (Powell et al., 1992). A
major role of APC in growth control is due to its function in the
WNT signaling pathway and its effects on β-catenin degradation
(reviewed in Goss and Groden, 2000).
Other individuals present with fewer colorectal adenomas
(less than 100), develop colorectal carcinoma at an older age
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than those with FAP, and carry germline mutations in APC that
lie in the 5′ and 3′ regions outside the common regions of muta-
tion; these individuals usually have a family history of colorectal
adenoma/carcinoma and are described as having attenuated
polyposis (AAPC). Still other individuals present with less than
100 colorectal adenomas, generally without a family history of
colorectal adenoma/carcinoma, and are described as having
“multiple colorectal adenomas.”
Al-Tassan et al. (2002) studied a family with multiple colo-
rectal adenomas and carcinoma predisposition, but no germline
APC defect, and found that tumors from family members
demonstrated a high incidence of somatic mutations in APC
that involved G:C → T:A transversions. These types of APC
mutations are uncommon in tumors from classic FAP individu-
als or in sporadic colorectal tumors. Oxidative DNA damage
leads to the formation of a particularly stable product, 8-oxogua-
nine (8-oxoG), which can pair with cytosine or mispair with ade-
nine. If repair does not occur, 8-oxoG:A base pairs can be
converted to T:A base pairs during subsequent replication. The
mutT homolog MTH removes oxidized nucleotide precursors
from the nucleotide pool prior to incorporation into DNA, 8-oxoG
glycosylase (OGG) excises 8-oxoG from 8-oxoG:C base pairs,
and MUTYH excises adenine from 8-oxoG:A base pairs.
Consequently, Al-Tassan et al. searched for germline mutations
in MTH, OGG1, and MUTYH and found inherited biallelic muta-
tions in MUTYH. Functional analysis of the most common
MUTYH variants, Y165C and G382D, was performed by mutat-
ing the corresponding conserved residues in E. coli mutY; the
protein products of these alleles demonstrated a significant
reduction in adenine glycosylase activity.
Additional studies confirmed the association of mutated
MUTYH with some cases of multiple colorectal adenoma and
some rare FAP cases and verified the recessive transmission of
MUTYH-associated polyposis (MAP) (Jones et al., 2002;
Sampson et al., 2003; Sieber et al., 2003). Heterozygous
germline MUTYH mutations have been detected in individuals
with colorectal cancer, but the larger scale studies required for
determining whether there is an increased colorectal cancer
risk in individuals heterozygous for MUTYH mutation have yet to
be performed (Halford et al., 2003; Sampson et al., 2003; Sieber
et al., 2003). Somatic mutation of MUTYH has not been
observed in sporadic colorectal cancers (Halford et al., 2003);
however, MUTYH maps to 1p32-34 (Slupska et al., 1996), a
genomic region where loss of heterozygosity (LOH) is a fairly
common event in colorectal tumorigenesis. It has recently been
observed that tumors from individuals heterozygous for MUTYH
mutations may have a higher than expected frequency of 1p
LOH (Kambara et al., 2004).
Genetic pathways in colorectal cancer
As colorectal carcinoma generally develops over the course of
years, usually through the readily identifiable precancerous
adenoma, this tumor type has provided a valuable paradigm for
the study of tumor progression. The identification of MUTYH
mutation in association with familial susceptibility to colorectal
adenoma and carcinoma and the role of MUTYH in BER have
amended the way in which we think of gastrointestinal tumor
progression.
Colorectal carcinomas develop according to specific genet-
ic pathways (Chung, 2000). A common feature of these path-
ways is the development of genomic instability, an important
event in multistep carcinogenesis since it provides for the accu-
mulation of genetic mutations. The most common pathway for
colorectal carcinoma development is the pathway characterized
by mutation of the APC, KRAS, SMAD4, and TP53 genes and
an aneuploid/polyploid karyotype. Some term this pathway
“CIN” to represent this type of variability in chromosome num-
ber. Other colorectal cancers develop through the “microsatel-
lite instability” (MSI) pathway. Microsatellites are short repetitive
sequences distributed throughout the human genome in which
frequent alterations of length correlate with mismatch repair
defects (Dietmaier et al., 1997). Tumors that develop through
this pathway have lower mutation frequencies of APC, KRAS,
SMAD4, and TP53, higher mutation frequencies of TGFβRII,
IGFFIIR, BAX, BRAF, and E2F4, and a near-diploid karyotype.
An additional subset of tumors demonstrates neither an excess
of major chromosomal abnormalities nor microsatellite instabili-
ty (Georgiades et al., 1999; Yao et al., 1999). This has suggest-
ed the existence of at least one additional pathway to
tumorigenesis (CIN−, MSI−).
In FAP, tumor formation generally (but not always) occurs by
the CIN pathway (Konishi et al., 1996), presumably at least par-
tially due to a role of APC in chromosome segregation that is
independent of its role in signal transduction (Fodde et al.,
2001; Kaplan et al., 2001). Other acquired mutations in onco-
genes and tumor suppressor genes are likely to work in synergy
with APC mutation in creating chromosomal instability (Fodde
et al., 2001). In hereditary nonpolyposis colorectal cancer
(HNPCC), which results from germline mutations in genes
encoding mismatch repair proteins, usually MSH2 or MLH1, but
also MSH6, PMS2, or PMS1 (Narayan and Roy, 2003), tumors
generally develop via the MSI pathway (Konishi et al., 1996;
Muller and Fishel, 2002). Lipton et al. (2003) examined MAP
tumors and determined that the MAP pathway is distinct from
the CIN and MSI pathways but shares some features with each
of the other pathways. Consistent with a BER defect, G:C → T:A
transversions were found in APC and KRAS; p53 overexpres-
sion was common. SMAD4, TGFBIIR, and BRAF were not
mutated, and the karyotype was near-diploid. Thus, the MAP
pathway can be characterized as CIN−, MSI− (Table 1).
Although colorectal tumors can develop instability via the
CIN pathway, the MSI pathway, or a BER defect (CIN−, MSI−
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Table 1. Major mutational pathways in colorectal cancer
Type of genomic instability CIN chromosomal instability MSI microsatellite instability CIN−, MSI−
Karyotype aneuploid/ polyploid near-diploid near-diploid
Common somatic gene APC, KRAS, SMAD4, TP53 TGFβRII, IGFFIIR, BAX, BRAF, MSH3, MSH6, E2F4; APC, KRAS
mutation/inactivation fewer APC, KRAS, SMAD4, and TP53 mutations
Familial colorectal cancer FAP (via APC defect) HNPCC (primarily via MSH2 or MLH1 defect; rarely  MAP (via MUTYH defect/
syndrome associated with MSH6, PMS2, or PMS1 defect/MMR defect) BER defect)
pathway
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pathway), they tend to develop a single type of instability. This
may be due to a lack of selective pressure for additional sources
of instability or to the compromise of cell survival by “too much”
instability (Cahill et al., 1999). Numerous mutations and epige-
netic effects are likely to modify the progression of cells along
each of these pathways. For a more in-depth discussion of
genetic instability and pathways to tumorigenesis in colon can-
cer, the reader is referred to Ilyas et al. (1999).
MUTYH and connections among DNA repair pathways
The association of human MUTYH with apurinic/apyrimidinic
endonuclease (APE1), proliferating cell nuclear antigen
(PCNA), and replication protein A (RPA) suggests a role for
MUTYH in long-patch BER (Parker et al., 2001). In addition, the
cell cycle-dependent expression of MUTYH and its colocaliza-
tion with replication foci suggest that its repair function is cou-
pled to replication (Boldogh et al., 2001). The recent findings
that MUTYH physically interacts with the MSH2/MSH6 het-
erodimer (the human MutSα homolog involved in MMR) via
MSH6 and that the MSH2/MSH6 heterodimer stimulates the
DNA binding and glycosylase activities of MUTYH in the pres-
ence of an 8-oxoG:A mismatch suggest cooperation between
BER and MMR in the repair of this type of oxidative damage (Gu
et al., 2002). Since both MUTYH and MSH2/MSH6 interact with
PCNA, PCNA may have a role in coordinating the BER and
MMR pathways to accomplish the repair of these lesions.
Identification of the DNA repair protein BRCA2 as a
Fanconi anemia protein
Another recent finding provides new information about connec-
tions among repair pathways. The discovery that the BRCA2
gene is the Fanconi anemia gene D1 (FANCD1) has linked the
genes responsible for seemingly unrelated cancer predisposi-
tion syndromes to a common pathway (Howlett et al., 2002).
Fanconi anemia (FA) is a rare multigenic autosomal
recessive cancer susceptibility syndrome characterized by pro-
gressive bone marrow failure, congenital abnormalities, hyper-
sensitivity to crosslinking agents (such as mitomycin C and
cisplatin), a more modest hypersensitivity to ionizing radiation
(IR) and oxygen radicals, and the development of hematologic
and solid tumors. At the cellular level, it is characterized by
spontaneous chromosomal breakage. Somatic cell genetics
and complementation analysis first identified at least eight dis-
tinct FA genes (A, B, C, D1, D2, E, F, G); six were subsequently
cloned (A, C, D2, E, F, G). The protein products of five of these
genes (A, C, E, F, and G) form a multisubunit nuclear core com-
plex (reviewed in D’Andrea and Grompe, 2003). Recently, a
sixth component of the nuclear core complex was identified as
the ubiquitin ligase PHF9 or FANCL (Meetei et al., 2003a), and
a seventh component was identified as Fanconi anemia-associ-
ated polypeptide 95 (FAAP95) or FANCB (Meetei et al., 2004).
There is also new evidence for the existence of additional
Fanconi anemia genes (Levitus et al., 2004).
During S phase or in response to DNA damage, the FA
nuclear core complex mediates the monoubiquitination of the
downstream FANCD2 protein and targets it to nuclear foci,
where it becomes colocalized with BRCA1 (Garcia-Higuera et
al., 2001). To investigate the associations between the breast
cancer susceptibility genes, BRCA1 and BRCA2, and the FA
genes, Howlett et al. (2002) sequenced BRCA1 and BRCA2 in
cells derived from individuals with FA subtype B (FA-B) and FA
subtype D1 (FA-D1), the two subtypes for which the corre-
sponding genes had not yet been identified. They failed to
detect mutations in BRCA1 but detected biallelic truncating
mutations in BRCA2 in both FA-B and FA-D1 cell lines. When
full-length BRCA2 was expressed in a FA-D1 cell line, a correc-
tion of mitomycin C sensitivity was observed, confirming that
BRCA2 is a Fanconi anemia protein.
R E V I E W
Figure 1. Simplified model of the FA/BRCA pathway in DNA repair and
checkpoint control
Several FA proteins (including A, B, C, E, F, G, and L) form a core complex in
the nucleus of human cells. Other DNA repair proteins, including BLM and
BRCA1, associate with the FA nuclear core complex. The FA/BRCA path-
way is most likely activated by double-strand breaks formed directly by
ionizing radiation (IR) or indirectly by the initiation of interstrand crosslink
repair (Rothfuss and Grompe, 2004). The FA nuclear core complex medi-
ates the monoubiquitination (Ub) of FANCD2 at lysine 561 (K561), probably
by the monoubiquitin ligase FANCL; this modification is associated with the
translocation of FANCD2 to DNA repair foci. Efficient FANCD2 monoubiqui-
tination may also be dependent on the ATR kinase (represented by the
arrow of dots and dashes). Although BRCA1 has monoubiquitin ligase
activity when bound to BARD1, it is not required for the monoubiquitination
of FANCD2 in vivo; BRCA1 is required for the translocation of FANCD2 to
DNA repair foci (Vandenberg et al., 2003). Numerous DNA repair proteins
accumulate in these foci, including those represented in this schematic
(BRCA1, BRCA2/FANCD1, RAD51, RMN complex, BLM, and WRN).
Numerous associations among proteins localized to repair foci have been
reported, but the exact composition of repair complexes is unknown. The
FA/BRCA pathway is regulated by the ATR and ATM kinases.
Phosphorylations of a number of substrates, including CHK kinases, the
NBS1 subunit of the RMN complex, BRCA1, and FANCD2 are involved in
activation of the S phase checkpoint. ATR and ATM also phosphorylate
several of the proteins that localize to DNA repair foci and presumably play
a role in the repair process (represented by dashed arrows to repair focus).
The functional implications of these modifications are largely unknown.
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Role for the FA/BRCA pathway in DNA repair and check-
point control
The FA and BRCA proteins most likely function in a common
pathway that regulates several aspects of the cellular response
to DNA damage (Figure 1). After DNA damage, the FA nuclear
core complex activates the monoubiquitination of FANCD2 at
lysine 561. This modification mediates the targeting of FANCD2
to DNA repair foci in which it colocalizes with BRCA1 (Garcia-
Higuera et al., 2001) and RAD51 (Taniguchi et al., 2002a), the
protein that facilitates pairing and strand exchange during HR.
Interestingly, the monoubiquitination and relocalization of
FANCD2 occurs in response to DNA damage initiated by mito-
mycin C, IR, or UV light (Garcia-Higuera et al., 2001), types of
damage that require different but overlapping repair mecha-
nisms. In this context, it should be noted that BRCA1 is present
in large protein complexes in association with a variety of DNA
repair proteins, including: the MMR proteins MSH2, MSH6, and
MLH1; ATM (ataxia telangiectasia mutated), a serine-threonine
kinase which phosphorylates a number of S phase checkpoint
and DNA repair proteins; BLM, a recQ-like helicase involved in
repair via HR; the RAD50-MRE11-NBS1 (RMN) complex, which
functions in both HR and NHEJ; and replication factor C (RFC),
which facilitates the association of PCNA with DNA (Wang et
al., 2000).
BRCA2/FANCD1 is present in DNA repair foci containing
activated FANCD2, BRCA1, and RAD51, and binds both to
DNA and RAD51 (Davies et al., 2001). Recent studies demon-
strate a direct interaction between BRCA2/FANCD1 and
FANCD2 and indicate that monoubiquitinated FANCD2 pro-
motes BRCA2 recruitment to DNA-damage inducible foci
(Hussain et al., 2004; Wang et al., 2004). BRCA2/FANCD1 may
be involved in the assembly of RAD51 into repair foci (Digweed
et al., 2002). Studies in Brca2-deficient ES cells (Tutt et al.,
2001) and in FA-D1 cells (Digweed et al., 2002) suggest that
mutations in BRCA2/FANCD1 result in the use of the less accu-
rate, RAD51-independent HR pathway, single strand annealing,
rather than the more accurate, RAD51-dependent HR pathway,
gene conversion.This is consistent with the chromosomal insta-
bility observed in Fanconi anemia and BRCA2−/− cells. It is also
consistent with the sensitivity to DNA crosslinking agents
observed in these cells, since interstrand crosslink repair
requires both NER and HR (de Silva et al., 2000). Daniels et al.
(2004) have recently described abnormal cytokinesis in
BRCA2-deficient cells, suggesting that such a defect could be
an additional cause for chromosomal instability in these cells.
Although numerous details remain to be worked out, the
FA/BRCA pathway is apparently regulated by both ATR (ATM-
and Rad3-related) and ATM kinases. After IR treatment,
FANCD2 is phosphorylated in an ATM-dependent manner
(Taniguchi et al., 2002b), while after treatment with crosslinking
agents, it is phosphorylated in an ATR-dependent manner
(Pichierri and Rosselli, 2004). Recently, two ATR-dependent
pathways induced by interstrand crosslinks and which coopera-
tively result in full S phase checkpoint activation have been
described (Pichierri and Rosselli, 2004). Activation of the ATR-
CHK1 pathway depends upon the phosphorylation of CHK1 by
ATR. Activation of the ATR-NBS1-FANCD2 pathway depends
upon the FA nuclear complex-dependent assembly of the RMN
complex and the translocation of FANCD2 to nuclear foci, the
phosphorylation of NBS1 by ATR, and the NBS1-dependent
phosphorylation of FANCD2 by ATR. Another recent study sug-
gests that ATR may be required for the efficient monoubiquitina-
tion of FANCD2 in response to various types of DNA damage
(Andreassen et al., 2004). Although FANCD2 is a substrate of
ATR in vitro, the mechanism of ATR-dependent activation of
FANCD2 by monoubiquitination is unknown.
After exposure to IR, ATM phosphorylates FANCD2 on ser-
ine 222, and this phosphorylation is required for activation of the
S phase checkpoint (Taniguchi et al., 2002b). ATM also phos-
phorylates other substrates involved in the S phase checkpoint,
including NBS1, CHK2, and BRCA1; the relative and/or cooper-
ative contributions of these protein modifications have yet to be
determined.
Not surprisingly, biallelic disruption of FANCD2 results in an
S phase checkpoint defect and hypersensitivity to both
crosslinking agents and IR. Future studies of proteins that inter-
act with activated FANCD2 should be helpful in gaining an
understanding of how S phase checkpoints and DNA repair are
accomplished at the molecular level.
The recQ-like helicase BLM functions in pathways that
respond to various types of DNA damage
Recent studies indicate that the recQ-like helicases (reviewed
in Bachrati and Hickson, 2003; Risinger and Groden, 2004),
another family of DNA repair proteins which have a major role in
the maintenance of genomic stability, are also likely to function
in a common pathway that responds to various types of DNA
damage. The recQ-like helicases are named for the similarity of
family members to the prototype E. coli recQ helicase that par-
ticipates in the bacterial recF genetic recombination pathway.
They are ATP- and Mg2+-dependent 3′-5′ helicases, i.e., they
translocate along the DNA strand to which they bind in the 3′-5′
direction as they unwind duplex DNA. RecQ-like helicases are
unusual among helicases in their DNA substrate preferences.
They are generally unable to unwind blunt-ended duplex DNA
unless a bubble is present, but they efficiently unwind such non-
Watson-Crick DNA structures as G quadruplexes (extremely
stable DNA secondary structures that can form in guanine-rich
regions of DNA) and Holliday junctions (four-way crossover
structures formed by DNA strand exchange during HR or in the
resolution of stalled replication forks). They also efficiently
unwind D loops (intermediates formed during the strand inva-
sion step of recombination).
In humans, there are 5 recQ-like helicases, encoded by the
BLM, RECQL (also referred to as RECQ1), RECQL4, RECQL5,
and WRN genes. Defects in three of the human recQ-like heli-
cases result in chromosome breakage syndromes (autosomal
recessive human disorders characterized by spontaneous chro-
mosome breakage); germline defects in BLM, RECQL4, and
WRN are responsible for Bloom syndrome, Rothmund-
Thomson syndrome, and Werner syndrome, respectively. In
addition to chromosome instability at the cellular level, these
rare diseases are characterized by striking cancer susceptibility,
although each to a unique tumor spectrum. Due to space limita-
tions, this review will focus on the recQ-like helicase BLM. For
recent discussions of recQ-like helicases and their roles in
maintaining genomic stability and suppressing tumorigenesis
that also include RECQL4 and WRN, the reader is referred to
Bachrati and Hickson (2003) and Risinger and Groden (2004).
Individuals with Bloom syndrome (BS) are proportional
dwarfs with sun-sensitive facial erythema, male infertility,
immune deficiency, and an unusually high incidence of nearly
all forms of cancer at an early age (average 24 years). The hall-
mark of BS cells, and a feature which is considered diagnostic
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of the disease, is a multifold increase in the frequency of sister
chromatid exchange, the reciprocal exchange of DNA between
sister chromatids by homologous recombination. An abnormal
profile of DNA replication intermediates is also characteristic of
BS cells.
BLM is expressed in all tissues in which there is active cell
proliferation. It is barely detectable in cells during the G1 phase
of the cell cycle, but dramatically increases in amount during the
S and G2 phases. BLM generally has a punctate nuclear distrib-
ution that partially overlaps with PML bodies, named for the
presence of promyelocytic leukemia tumor suppressor protein.
After treatment of cells with DNA replication inhibitors or DNA
damaging agents, BLM associates with sites of DNA
damage/repair, defined by the presence of phosphorylated his-
tone H2AX or RAD51 and thought to be sites of stalled replica-
tion forks.
A number of other BLM-protein associations have been
described, many of which result in alterations in the activity of
BLM or the associated protein and provide explanations for
some of the proposed functions of BLM in replication, recombi-
nation, and repair. RPA, a single-stranded DNA binding protein
involved in replication, recombination, and repair, physically
interacts with BLM and stimulates its helicase activity (Brosh et
al., 2000). BLM binds topoisomerase IIIα (TOPO IIIα) and stim-
ulates its DNA strand passage activity (Wu and Hickson, 2002,
2003). BLM also interacts with 5′-flap endonuclease/5′-3′
exonuclease (FEN-1; involved in Okazaki fragment processing
and in primarily BER and NHEJ DNA repair pathways) and
stimulates both the endonuclease and the exonuclease activi-
ties of FEN-1 on a variety of DNA substrates that represent
intermediates in DNA replication and repair (Sharma et al.,
2004).
The RAD51 paralog RAD51D binds to BLM, and the
RAD51D-XRCC2 complex stimulates the ability of BLM to
process synthetic Holliday junctions in vitro (Braybrooke et al.,
2003). In contrast, the tumor suppressor p53 binds to BLM and
attenuates its ability to unwind synthetic Holliday junctions in
vitro (Yang et al., 2002). BLM associates with the MMR proteins
MLH1 (Langland et al., 2001) and MSH6; the MSH2/MSH6 het-
erodimer regulates the ability of BLM to process synthetic
Holliday junctions in vitro (Yang et al., 2004). BLM-deficient
cells, however, do not demonstrate a MMR defect (Langland et
al., 2001), suggesting that these MMR proteins may play a role
in HR repair. BLM-deficient cells do demonstrate defects in
NHEJ (Langland et al., 2002).
BLM is also likely to have a role(s) in the FA/BRCA pathway
(Figure 1). BLM has been isolated from human HeLa cell
extracts in a complex containing the FA nuclear core complex,
RPA, and TOPO IIIα; this complex has DNA unwinding activity
that is dependent on the presence of BLM (Meetei et al.,
2003b). Pichierri et al. (2004) have recently shown that the FA
nuclear core complex is necessary for BLM phosphorylation
and recruitment to nuclear foci in response to DNA crosslinking
agents. Monoubiquitination of FANCD2 occurs normally in BS
cells; however, BLM and monoubiquitinated FANCD2 colocalize
and coimmunoprecipitate after replication arrest or treatment
with crosslinking agents. As other proteins that function in the
FA/BRCA pathway, BLM associates with, and is phosphorylated
by, the ATM (Beamish et al., 2002) and ATR kinases (Franchitto
and Pichierri, 2002; Davies et al., 2004) after specific types of
DNA damage. BLM is one of the first proteins to relocalize to
sites of DNA damage/repair and binds directly to RAD51 (Wu et
al., 2001). BLM may subsequently recruit p53 (Sengupta et al.,
2003), BRCA1 (Davalos and Campisi, 2003), and RMN
(Franchitto and Pichierri, 2002; Davalos and Campisi, 2003) to
sites of stalled replication forks/DNA repair.
In general, loss of recQ-like helicase function results in
abnormal DNA replication and increased recombination. These
helicases have unusual substrate preferences that include G
quadruplexes, structures that resemble Holliday junction recom-
bination intermediates and D loops.They associate with numer-
ous proteins implicated in replication, recombination, and
repair, and associate with stalled replication forks after replica-
tion has been interrupted or DNA damage has occurred. These
data suggest that the major function of recQ-like helicases is to
restart stalled replication forks and thereby maintain genomic
stability. Mechanistically, recQ-like helicases may reset replica-
tion forks stalled after encountering DNA damage, and/or they
may have a role in repair of stalled forks by HR, while suppress-
ing the production of “nonparental” recombinants. They may
also resolve DNA secondary structures such as G quadruplex-
es ahead of the replication fork.
Interestingly, the recQ helicases BLM and WRN interact
with one another; BLM can inhibit the exonuclease activity of
WRN (von Kobbe et al., 2002). The synergistic increase in
hypersensitivity to DNA damaging agents in BLM−/−/WRN−/−
chicken DT40 cells (Imamura et al., 2002), the major differences
in the human syndromes, and the unique patterns of somatic
cell chromosome instability suggest that BLM and WRN have
largely complementary rather than redundant roles in DNA
repair. One can argue that there may be some overlap in func-
tion, as loss of function of a single recQ helicase is compatible
with survival in humans. As BLM and WRN interact with and
recruit numerous types DNA repair proteins to sites of damage
and both undergo numerous posttranslational modifications,
they may indeed be involved in coordinating DNA repair path-
ways.
Future perspectives
The next few years hold great promise for the study of human
cancer syndromes associated with DNA repair defects.
Identifying interactions of DNA repair proteins and the effects of
these interactions on enzymatic function and signaling will no
doubt continue to be an exciting avenue of research. Little is
currently known about the in vivo processing of specific DNA
structures created by different types of damage and the pro-
cessing of specific repair intermediates. How one repair mecha-
nism is chosen over another and how repair mechanisms might
be utilized in sequence are also unknown. Understanding the
links between repair mechanisms, cell cycle regulation, and
apoptotic mechanisms will require further investigation. Recent
studies and those performed nearly thirty years ago suggest
that heterozygosity for loss of function mutations in DNA repair
genes may be associated with increased cancer risk (Goss 
et al., 2002; Gruber et al., 2002; and Swift et al., 1976).
Consequently, validation of these studies in large populations
and the study of how more subtle DNA repair protein sequence
variants affect human disease risk in the general population are
indicated.
Recent advances in imaging, mouse modeling, microarray
analysis, and proteomic technologies will make it possible to
study gene and protein expression in individual tumors and pro-
vide additional perspectives on the role of DNA repair proteins
in tumor initiation and progression.This, in turn, will assist in the
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design of new types of therapeutic agents. More exciting is the
possibility that understanding the DNA repair capacity of an
individual or the capacity of a specific tumor may enable the
personalized choice of effective therapeutic agents, most of
which function by producing specific types of DNA damage in
cancer cells. The great gifts of nature’s experiments in human
variation have given us a wonderful beginning to understand
how genomic integrity is maintained.
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